ClinicalTrials.gg
TerminatedNCT01856023PROCLIVITY02Updated Dec 5, 2023Results posted

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

A Phase 4 interventional study of High Dose Interleukin-2 and Ipilimumab in Metastatic Melanoma, sponsored by Clinigen, Inc.. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Clinigen, Inc. · Phase 4, Interventional, and Treatment

Why this study was terminated
slow accrual \& early closure

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing Interleukin-2 in Melanoma — none open to participants now, 2 under way, none of them phase 3. Interleukin-2 · Melanoma.

Enrollment
11th of 41
29 · median 15
Started
2013
with 2 others
Phase 4
Only one
of the 43
Registered
30th of 43
by date
Lead sponsor
1 of 43
Clinigen, Inc.

Among the 43 studies testing Interleukin-2 in Melanoma, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2013, is the only one in phase 4, and was the 30th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 43 studies testing Interleukin-2 in Melanoma is open now. The open studies under Melanoma, anywhere →

About Interleukin-2

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies testing Interleukin-2 in Melanoma as a file.
02

Study summary

Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.

Treatment Arm 1: "HD IL-2 first, then ipilimumab" Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.

Treatment Arm 2: Ipilimumab first then HD IL-2 Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.

Read the detailed description

All patients will receive IL-2 at 600,000 international units per kilogram (kg) by intravenous bolus (IVB) every 8 hours for up to 14 planned doses with an additional cycle 14 days after the first.

Ipilimumab 3mg/kg IV infusion Q3 weeks up to 4 doses4 doses A 3-6 week interval been the administration of the two drugs to allow for resolution of treatment-related toxicities.

If corticosteroids were required during Ipilimumab administration, a 2-week period from discontinuation of steroid treatment to start of HD IL-2.

03

Conditions studied

  • Metastatic Melanoma

Keywords

  • melanoma
  • metastatic
  • skin cancer
  • Stage IV
  • interleukin-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 18 years or older
  • Confirmed and measurable melanoma with at least one for evaluation of response
  • Meets the requirements for HD IL-2 therapy per Institutional guidelines
  • Meets the requirements for ipilimumab therapy per Institutional guidelines
  • Treatment naïve or has received only one systemic therapy apart from therapy.
  • At least 4 weeks since last adjuvant therapy or other cancer treatment
  • Willing and able to give and participate in study procedures as described in the 12PLK02 and 10PLK13 protocols. Patients consented for 12PLK02 will also be asked to participate in the 10PLK13 PROCLAIM registry study.

Exclusion criteria

Exclusion Criteria:

  • Patients with known or suspected infection with (HIV), virus (HCV), virus (HBV) or other infectious hepatitis
  • Pregnant, nursing or planning to become pregnant
  • Untreated . (Brain metastases that have been treated, which no longer require therapy and are without progression by MRI at least 6 weeks after definitive therapy are acceptable.)
  • Received prior ipilimumab therapy (Prior Adjuvant Ipilimumab and Adjuvant Interferon are permitted with a minimum 4 week washout)
  • Received prior HD IL-2 therapy.
  • Received drug within 30 days prior to study dosing. Patients may participate in non-interventional or observational clinical studies, including the 10PLK13 PROCLAIM registry study.
  • Concomitant disease or condition that would interfere with the conduct of the study or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    Treatment Arm 1

    Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.

    Drug: High Dose Interleukin-2 · Drug: Ipilimumab

  • Active comparator
    Treatment Arm 2

    Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.

    Drug: High Dose Interleukin-2 · Drug: Ipilimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Estimated One-year OS in the Evaluable Population in Each Treatment Arm Separately

    evaluable patients who received at least 50% of both research drugs and had their disease re-evaluated after baseline; defined in days for the start of the first treatment to death. percent of patients alive at 1 year; estimates were assessed using Kaplan-Meier method for the entire subject population for each treatment arm separately.

    Time frame: start of first treatment to date of death from any cause and patients alive at their last evaluation date were censored up to 1 year.

Secondary outcomes

  1. Progression-free Survival

    duration of time (in Days) from start of the first treatment to the time of objective disease progression or death at one year. The immune-related response criteria (irRC) determined based on tumor burden calculated on the WHO method of multiplying the perpendicular dimensions of all lesions are summed to obtain the tumor burden. The total tumor burden + SPD (index lesions) + SPD (new measurable lesions) Based on CT scans and Physical exam at designated timepoints. CR- Disappearance of all known disease; PR\>/equal to decrease; SD Neither CR or PD; PD 25%increase; new lesion.

    Time frame: 5-11 weeks, 13-19 Weeks, 24-30 weeks and 1 year

07

Results

Posted Dec 5, 2023
Limitations and caveats
This study enrollment planned for 50 in each arm; but ended early 29 pts enrolled due to change in treatment options; the purpose of the study was to determine which sequence of approved therapy was more effective and safe; this was not a planned cross-over study complete data collection and final summary is limited due to limited data available Due to sponsor changes, and databases are no longer available.

Participant flow

Study initiation Sept 11, 2013 - Early Study Termination August 18, 2015 Planned accrual 50 pts/ arm.

Participant flow — Overall Study
MilestoneTreatment Arm 1 HD IL-2 1st Followed by IpilimumabTreatment Arm 2 Ipilimumab 1st Followed by HD IL-2
Started1316
Intent to treat: received one dose of study drug1216
Evaluable: received 50% of each study drug810
Completed34
Not completed1012
Withdrew: Death12
Withdrew: Adverse event21
Withdrew: Lack of efficacy55
Withdrew: Non compliance, study closure13
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryEstimated One-year OS in the Evaluable Population in Each Treatment Arm Separately

evaluable patients who received at least 50% of both research drugs and had their disease re-evaluated after baseline; defined in days for the start of the first treatment to death. percent of patients alive at 1 year; estimates were assessed using Kaplan-Meier method for the entire subject population for each treatment arm separately.

Time frame:
start of first treatment to date of death from any cause and patients alive at their last evaluation date were censored up to 1 year.
Reported as:
Number · percentage of participants
Estimated One-year OS in the Evaluable Population in Each Treatment Arm Separately
percentage of participantsTreatment Arm 1Treatment Arm 2
Estimated One-year OS in the Evaluable Population in Each Treatment Arm Separately73 (38 to 91)75 (40 to 92)
Statistical analysis
  • Treatment Arm 1 vs Treatment Arm 2 · Log Rank · p = .001 (compared to the historical control rate of 46% one year survival)
SecondaryProgression-free Survival

duration of time (in Days) from start of the first treatment to the time of objective disease progression or death at one year. The immune-related response criteria (irRC) determined based on tumor burden calculated on the WHO method of multiplying the perpendicular dimensions of all lesions are summed to obtain the tumor burden. The total tumor burden + SPD (index lesions) + SPD (new measurable lesions) Based on CT scans and Physical exam at designated timepoints. CR- Disappearance of all known disease; PR\>/equal to decrease; SD Neither CR or PD; PD 25%increase; new lesion.

Time frame:
5-11 weeks, 13-19 Weeks, 24-30 weeks and 1 year
Reported as:
Median · days
Progression-free Survival
daysTreatment Arm 1 HD IL-2 1st Followed by IpilimumabTreatment Arm 2 Ipilimumab 1st Followed by HD IL-2
Progression-free Survival58 (18 to 84)80 (41 to 95)

Adverse events

Collected over Adverse events were monitored/ assessed for up to 30 weeks after 1st dose of study drug. All -cause mortality monitored/assessed up to 1 year.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm 1 HD IL-2 Administered 1st Followed by Ipilimumab1/13 (7.7%)9/13 (69.2%)9/13 (69.2%)
Treatment Arm 2 Ipilimumab Administered 1st Followed by HD IL-22/16 (12.5%)10/16 (62.5%)10/16 (62.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventTreatment Arm 1 HD IL-2 Administered 1st Followed by IpilimumabTreatment Arm 2 Ipilimumab Administered 1st Followed by HD IL-2
supraventricular tachycardia, ventricular tachycardiaCardiac disorders2/130/16
Autoimmune encephalitis, intracranial HemorrhageNervous system disorders2/130/16
colitisGastrointestinal disorders0/132/16
PneumoniaInfections and infestations0/132/16
Respiratory Failure, HypoxiaRespiratory, thoracic and mediastinal disorders1/132/16
DiarrheaGastrointestinal disorders1/130/16
back pain, neck painMusculoskeletal and connective tissue disorders1/130/16
ThrombocytopeniaBlood and lymphatic system disorders1/130/16
embolismVascular disorders1/130/16
wound infectionInfections and infestations1/130/16
Most frequent other events
Showing 10 of 25
Most frequent other events
EventTreatment Arm 1 HD IL-2 Administered 1st Followed by IpilimumabTreatment Arm 2 Ipilimumab Administered 1st Followed by HD IL-2
Acute Kidney InjuryRenal and urinary disorders8/132/16
diarrheaGastrointestinal disorders4/131/16
Back pain, neck painMusculoskeletal and connective tissue disorders4/130/16
increased creatinineBlood and lymphatic system disorders3/130/16
Muscular WeaknessMusculoskeletal and connective tissue disorders3/130/16
Peripheral EdemaGeneral disorders3/131/16
HypotensionVascular disorders3/131/16
FlushingVascular disorders3/130/16
Increased BUNBlood and lymphatic system disorders2/130/16
NauseaGastrointestinal disorders2/131/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment Arm 1 IL-2 FirstTreatment Arm 2 Ipi FirstTotal
<=18 years000
Between 18 and 65 years121426
>=65 years123
Age, Continuous
Age, Continuous(years)Treatment Arm 1 IL-2 FirstTreatment Arm 2 Ipi FirstTotal
Median49.5 (32 to 70)46 (20 to 69)48 (20 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm 1 IL-2 FirstTreatment Arm 2 Ipi FirstTotal
Female549
Male81220
Region of Enrollment
Region of Enrollment(participants)Treatment Arm 1 IL-2 FirstTreatment Arm 2 Ipi FirstTotal
United States131629
08

Study locations

12 sites
  • The University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Moores UCSD Cancer Center
    La Jolla, California 92093, United States
  • MSMC Research Program
    Miami Beach, Florida 33140, United States
  • Oncology Specialists, SC
    Park Ridge, Illinois 60068, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • Johns Hopkins Medicine
    Lutherville, Maryland 21093, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Nebraska Cancer Specialists, Midwest Cancer Center - Legacy
    Omaha, Nebraska 68130, United States
  • Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center
    New York, New York 10032, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2023, 8 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2013
First posted
May 17, 2013
Start
May 2013
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Dec 5, 2023
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01856023
Lead sponsor
Clinigen, Inc.
Responsible party
Sponsor
First posted
May 17, 2013
Start date
May 2013
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Dec 5, 2023
Last update
Dec 5, 2023

Study contacts

Sapna Patel, MD
principal investigator · MD Anderson
William Sharfman, MD
principal investigator · Johns Hopkins University
James Lowder, MD
principal investigator · Prometheus Labs

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Interleukin-2 · Ipilimumab

Start the discussion